- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00614354
Study of 99mTc-glucarate to Detect Acute Coronary Syndrome in Chest Pain Patients.
Phase II Study of 99mTc-glucarate in Chest Pain Patients Suspected With ACS With no Obvious Signs of AMI and With Known Previous CAD.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Acute coronary syndrome encompasses a range of coronary artery diseases, including unstable angina and both ST-segment elevation and non-ST-segment elevation myocardial infarction (MI). Differentiating ACS from noncardiac chest pain remains a challenge in the emergency department (ED). Myocardial perfusion imaging (MPI) for ischemia has been used to rule ACS in or out among chest pain patients with nondiagnostic ECGs upon presentation to the ED. Several studies have shown a high negative predictive value of MPI for ruling out acute ischemia in the emergency setting. Although myocardial imaging with perfusion agents provides important information for risk-stratifying stable post-ACS patients, this method is of limited value in patients with prior history of CAD, since these patients will often have abnormal resting perfusion patterns, thereby precluding the ability to differentiate old infarcts from new ischemic events. 99mTc-glucarate does not detect old MIs and thus should provide an improvement in specificity in the imaging of ACS patients with previous CAD.
This study proposes to extend the evaluation of 99mTc-glucarate imaging by studying its ability to detect ACS in chest pain patients with no obvious signs of AMI but with known CAD, in the setting of the ED. Unlike MPI, 99mTc-glucarate imaging will not detect old MIs, thereby providing an advantage in specificity of the technique.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35294
- University of Alabama at Birmingham
-
-
Connecticut
-
New Haven, Connecticut, United States, 06520
- Yale University
-
-
Ohio
-
Cleveland, Ohio, United States, 44106
- University Hospital Case Medical Center
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15213
- University of Pittsburgh Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Chest pain of recent onset (less than 24 hours) and of greater than 5-minute duration, consistent with ACS;
- History of CAD;
- Creatinine level less than 3.5 mg per deciliter;
- Female patients who are: surgically sterile (hysterectomy or bilateral tubule libation), at least one year post-menopausal, or have a negative pregnancy test on the day of treatment; and
- Written informed consent.
- This research is being supported by the NIH/NHLBI which requires a minimum 50% participation from women. Efforts should be made to enroll equal numbers of men and women at each clinical site.
Exclusion Criteria:
- ECG changes diagnostic of AMI;
- A cardiac revascularization procedure within the last 2 weeks (non-revascularization procedures such as cardiac catheterization, stress test or echocardiography are acceptable);
- An alternate diagnosis more probable than ACS;
- Presence of pericarditis, myocarditis, acute aortic dissection, pneumothorax, or pulmonary embolism (PE);
- Patients with uncontrolled severe heart failure at the time of enrollment (NYHA class III and IV).
- Other serious or life-threatening disease that might preclude a subject from completing this study;
- Clinically essential procedures with which this protocol may interfere;
- Previous 99mTc-based diagnostic test within the last 24 hours;
- Female subjects who are pregnant or lactating;
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 1
|
Patients will receive a single 22 - 27 mCi bolus intravenous dose of 99mTc-glucarate solution, as soon as possible after their arrival in the emergency department or the chest pain center
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Readers will assess images as either positive or negative and note the location of uptake.
Time Frame: Immediately and end of enrolement
|
Immediately and end of enrolement
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Albert J. Sinusas, MD, Yale University
- Study Chair: Diwakar Jain, MD, Drexel University
- Principal Investigator: Prem Soman, MD, Ph.D., University of Pittsburgh
- Principal Investigator: Ami E Iskandrian, MD, University of Alabama at Birmingham
- Principal Investigator: Robert S Jones, MD, University Hospitals Cleveland Medical Center
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- MTTI ACS 201
- 5R44HL062770-06 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Coronary Syndrome
-
Yonsei UniversityRecruitingCoronary Artery Disease, Acute Coronary SyndromeKorea, Republic of
-
Meditrix CorpNational University of Ireland, Galway, Ireland; Boston Scientific Japan K.K.; Fujita Health UniversityRecruitingChronic Coronary Syndrome | Non ST Segment Elevation Acute Coronary SyndromeJapan, Ireland
-
OrbusNeichDuke Clinical Research Institute; OrbusNeich Medical K.K.CompletedCoronary Arteriosclerosis | Non ST Segment Elevation Acute Coronary SyndromeUnited States, Japan
-
Medical University of WarsawRecruitingAcute Coronary Syndrome | Chronic Coronary Syndrome | Non ST Segment Elevation Acute Coronary SyndromePoland
-
Niguarda HospitalCompletedAcute Coronary Syndrome With ST Elevation on Electrocardiogram | Acute Coronary Syndrome Without ST Elevation on Electrocardiogram | Noncritical Coronary Artery Disease Coronary Stenosis Less Than 50 Per Cent | Aortic AneurysmsItaly
-
Sohag UniversityRecruitingLeft Main Coronary Artery Disease With Acute Coronary SyndromeEgypt
-
Eli Lilly and CompanyDaiichi Sankyo, Inc.CompletedCoronary Arteriosclerosis | Acute Coronary SyndromesUnited States
-
University of PatrasCompletedCoronary Artery Disease (CAD) | Acute Coronary Syndrome (ACS)Greece
-
Deutsches Herzzentrum MuenchenDeutsches Zentrum für Herz-Kreislauf-Forschung (DZHK)CompletedAcute Coronary Syndrome (ACS)Germany, Italy
-
Northwestern UniversityTerminatedACS - Acute Coronary SyndromeUnited States
Clinical Trials on 99mTc-glucarate solution
-
Technische Universität DresdenKlinikum Chemnitz gGmbHUnknown
-
Peking Union Medical College HospitalCompletedBreast CancerChina
-
Molecular Insight Pharmaceuticals, Inc.CompletedProstate CancerUnited States
-
Temple UniversityWithdrawnVenous ThrombosisUnited States
-
British Columbia Cancer AgencyCanadian Institutes of Health Research (CIHR); Lawson Health Research Institute and other collaboratorsCompleted
-
Peking Union Medical College HospitalCompleted
-
Peking UniversitySun Yat-sen University; China-Japan Union Hospital, Jilin UniversityCompleted
-
Peking Union Medical College HospitalRecruiting
-
Xijing HospitalNot yet recruiting99mTc-FAPI-positive Gastrointestinal Tumor
-
Mayo ClinicRecruitingAortic Stenosis | Transthyretin Amyloidosis | Transthyretin Cardiac Amyloidosis | Transthyretin Amyloid CardiomyopathyUnited States